The total return over the past 12 months is -49.83% vs. +16.94% for the S&P 500. So far it's up 0.00% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (66.20%) | (83.77%) | (88.28%) | (80.03%) | N/A | N/A |
| Total Return CAGR | (49.83%) | (82.05%) | (87.55%) | (79.42%) | N/A | N/A |
| Revenue CAGR | +196.02% | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Tonix Pharmaceuticals Holding Corp. (TNXP)
| Year | Start price | End price | TNXP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $15.62 | $8.07 | 0.00% | +14.51% | (14.51%) |
| 2025 | $32.98 | $15.62 | (66.67%) | +17.72% | (84.39%) |
| 2024 | $1,289.60 | $32.98 | (97.46%) | +24.89% | (122.35%) |
| 2023 | $7,796.00 | $1,289.60 | (83.45%) | +26.19% | (109.64%) |
| 2022 | $228,928.00 | $7,796.00 | (96.60%) | (18.17%) | (78.43%) |
| 2021 | $432,000.00 | $228,928.00 | (47.01%) | +28.74% | (75.75%) |
| 2020 | $748,800.00 | $432,000.00 | (42.31%) | +18.37% | (60.68%) |
| 2019 | $7,040,000.00 | $748,800.00 | (89.36%) | +31.22% | (120.58%) |
| 2018 | $36,796,320.00 | $7,040,000.00 | (80.87%) | (4.56%) | (76.31%) |
| 2017 | $50,138,985.00 | $36,796,320.00 | (26.61%) | +21.70% | (48.31%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
